It is suggested that the SHMT2–lactate–CAF axis contributes to the metabolic–stromal regulation of T-cell exclusion and may represent a potential therapeutic target for improving the response of immune-excluded HNSCC to PD-1 blockade.
Abstract
Resistance to PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) is frequently attributed to an “immune-excluded” tumor microenvironment (TME); however, the tumor-intrinsic metabolic drivers orchestrating this spatial remodeling remain poorly defined. Here, we identify serine hydroxymethyltransferase 2 (SHMT2) as a critical determinant of the immunosuppressive stromal niche. SHMT2 is aberrantly overexpressed in malignant cells, and its high expression correlates with a cancer-associated fibroblast (CAF)-rich, T-cell-excluded phenotype in HNSCC cohorts. While SHMT2 deficiency does not alter tumor growth in immunodeficient mice, it markedly suppresses tumor progression in immunocompetent hosts, suggesting an immune-dependent therapeutic effect. Integrated single-cell and spatial profiling reveal that SHMT2 loss reduces CAF accumulation and disrupts the CAF-mediated physical barrier, facilitating robust infiltration of CD4⁺ and CD8⁺ T cells into the tumor parenchyma, without inducing a general reduction in other immunosuppressive immune populations. Mechanistically, SHMT2-driven one-carbon metabolism maintains the S-adenosylmethionine (SAM) pool, which promotes H3K4me3 enrichment at the
LDHA
promoter to epigenetically activate its transcription. The resulting SHMT2–SAM–LDHA axis elevates lactate secretion, which acts as a paracrine signal to trigger CAF activation and spatial accumulation. Furthermore, pharmacological targeting of the SHMT2-dependent axis using SHMT-IN-2 effectively suppresses lactate-associated CAF remodeling and synergizes with anti-PD-1 therapy in vivo. These findings suggest that the SHMT2–lactate–CAF axis contributes to the metabolic–stromal regulation of T-cell exclusion and may represent a potential therapeutic target for improving the response of immune-excluded HNSCC to PD-1 blockade.
Findings identify NSUN2 as a critical orchestrator of T-cell exclusion in LUAD and serves as both a candidate predictive biomarker for ICI failure and a promising druggable target for immunotherapy resistance.
Wang-Yang Meng, Tong Lu, Ming-Yuan Du et al.· Experimental Hematology & On...· 0 citations
A novel epigenetic pathway orchestrated by PRMT5 that converges on the functional modulation of CBX8 to synchronously governs CD8⁺ T cell exclusion and tumor stemness is unveiled, nominating PRMT5 inhibition as a compelling therapeutic strategy for combination immunotherapy in TNBC.
Cong-Cong Chen, Yu-Heng Zhang, Chang Liu et al.· Oncogene· 0 citations
This study identifies a novel ‘PD-L1–ER stress–pyruvate–macrophage senescence’ axis as a key mechanism underlying primary resistance to ICB and proposes that targeting the PDK4/GLS-dependent pyruvate surge offers a promising therapeutic strategy to sensitize tumors to anti-PD-1 immunotherapy.
Wen-Xin Lian, Hui Yang, Yu-Qi Zhang et al.· Journal for ImmunoTherapy of...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.